Lv1
40 积分 2025-11-26 加入
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications
1个月前
已完结
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications
1个月前
已完结
Post-HCT maintenance therapy for AML: who, when, why, how long?
2个月前
已完结
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
2个月前
已完结
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
2个月前
已完结
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies
2个月前
已完结
Maintenance therapy with decitabine after allogeneic hematopoietic stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia
2个月前
已完结
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
2个月前
已完结
Azacitidine maintenance in AML post induction and posttransplant
2个月前
已完结
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis
2个月前
已完结
皖公网安备34019202002308
